SEQUENT WEEKLY long after breakout
Mis à jour
View is mine money is yours DYOR before investing or trading
expecting a bullish view in SEQUENT
About
Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.
Market Cap ₹ 3,533 Cr.
Current Price ₹ 142
High / Low ₹ 156 / 86.0
Stock P/E
Book Value ₹ 26.3
Dividend Yield 0.00 %
ROCE 0.90 %
ROE -2.46 %
Face Value ₹ 2.00
Promoter holding 52.8 %
Change in Prom Hold -0.01 %
Sales growth -3.60 %
Profit growth 73.3 %
Dividend yield 0.00 %
Current ratio 1.31
Profit after tax ₹ -16.7 Cr.
Price to book value 5.38
Sales ₹ 1,370 Cr.
Sales Qtr ₹ 361 Cr.
Qtr Sales Var -1.49 %
Qtr Profit Var 107 %
EVEBITDA 54.6
Return over 3months 13.3 %
Price to Earning
ROCE 0.90 %
Debt ₹ 488 Cr.
Return on equity -2.46 %
Cons
- Stock is trading at 5.38 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 5.68% over past five years.
- Company has a low return on equity of -1.84% over last 3 years.
- Can long after breakout expecting a quick move to 1st target
- cup and handle pattern
- DIIs increased their holding stake
Compounded Sales Growth
10 Years: 13%
5 Years: 6%
3 Years: 0%
TTM: -4%
Compounded Profit Growth
10 Years: 5%
5 Years: %
3 Years: %
TTM: 73%
Stock Price CAGR
10 Years: 7%
5 Years: 15%
3 Years: -22%
1 Year: 58%
Return on Equity
10 Years: 9%
5 Years: 4%
3 Years: -2%
Last Year: -2%
expecting a bullish view in SEQUENT
About
Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.
Market Cap ₹ 3,533 Cr.
Current Price ₹ 142
High / Low ₹ 156 / 86.0
Stock P/E
Book Value ₹ 26.3
Dividend Yield 0.00 %
ROCE 0.90 %
ROE -2.46 %
Face Value ₹ 2.00
Promoter holding 52.8 %
Change in Prom Hold -0.01 %
Sales growth -3.60 %
Profit growth 73.3 %
Dividend yield 0.00 %
Current ratio 1.31
Profit after tax ₹ -16.7 Cr.
Price to book value 5.38
Sales ₹ 1,370 Cr.
Sales Qtr ₹ 361 Cr.
Qtr Sales Var -1.49 %
Qtr Profit Var 107 %
EVEBITDA 54.6
Return over 3months 13.3 %
Price to Earning
ROCE 0.90 %
Debt ₹ 488 Cr.
Return on equity -2.46 %
Cons
- Stock is trading at 5.38 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of 5.68% over past five years.
- Company has a low return on equity of -1.84% over last 3 years.
- Can long after breakout expecting a quick move to 1st target
- cup and handle pattern
- DIIs increased their holding stake
Compounded Sales Growth
10 Years: 13%
5 Years: 6%
3 Years: 0%
TTM: -4%
Compounded Profit Growth
10 Years: 5%
5 Years: %
3 Years: %
TTM: 73%
Stock Price CAGR
10 Years: 7%
5 Years: 15%
3 Years: -22%
1 Year: 58%
Return on Equity
10 Years: 9%
5 Years: 4%
3 Years: -2%
Last Year: -2%
Transaction en cours
bought @140Transaction en cours
BREKOUT, Good volume and momentum still a buy zone
upper circuit move possible in next week
Trade fermée: cible de profit atteinte
3rd target hit 25% from my buy zone
still holding the trade full quantity
Note
next target : 202 ,225 ,240Note
TSL to 140Note
short term target hit all 3Trade fermée: cible de profit atteinte
50% move from my entry exited half quantity holding other half with a tailed stoploss
Transaction en cours
16% move today as i said Trade fermée: cible de profit atteinte
almost 70% from my entry , within 2 month
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.